Murphy Capital Management Has Lifted Goldman Sachs Group (GS) Position By $339,235; Oramed Pharmaceuticals, Inc. (ORMP) Covered By 3 Bullish Analysts Last Week

November 15, 2017 - By Marie Mckinney

Murphy Capital Management Inc increased Goldman Sachs Group (GS) stake by 28.72% reported in 2017Q2 SEC filing. Murphy Capital Management Inc acquired 1,535 shares as Goldman Sachs Group (GS)’s stock declined 13.97%. The Murphy Capital Management Inc holds 6,880 shares with $1.53 million value, up from 5,345 last quarter. Goldman Sachs Group now has $89.49 billion valuation. The stock decreased 1.29% or $3.1 during the last trading session, reaching $237.24. About 244 shares traded. Goldman Sachs Group Inc (NYSE:GS) has risen 39.23% since November 15, 2016 and is uptrending. It has outperformed by 22.53% the S&P500.

Among 3 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 6 analyst reports since August 14, 2015 according to SRatingsIntel. The company was initiated on Thursday, November 19 by FBR Capital. Zacks upgraded the stock to “Sell” rating in Friday, August 14 report. The company was initiated on Thursday, October 1 by H.C. Wainwright. The stock of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has “Buy” rating given on Friday, October 2 by Rodman & Renshaw. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 1 report. The firm earned “Buy” rating on Thursday, October 5 by H.C. Wainwright. See Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) latest ratings:

05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $25.0 Maintain

The stock increased 1.41% or $0.13 on November 14, reaching $9.36. About shares traded. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has risen 2.79% since November 15, 2016 and is uptrending. It has underperformed by 13.91% the S&P500.

Oramed Pharmaceuticals Inc. is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. The company has market cap of $124.68 million. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. It currently has negative earnings. The Firm is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Investors sentiment increased to 6 in 2017 Q2. Its up 5.57, from 0.43 in 2017Q1. It improved, as 0 investors sold Oramed Pharmaceuticals, Inc. shares while 1 reduced holdings. 5 funds opened positions while 1 raised stakes. 321,734 shares or 260.37% more from 89,279 shares in 2017Q1 were reported. Deutsche Comml Bank Ag, Germany-based fund reported 5 shares. Plante Moran Advisors Ltd Liability Corporation has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Tower Research Cap Ltd Liability Company (Trc) invested in 0% or 183 shares. Creative Planning owns 2,000 shares for 0% of their portfolio. Royal Savings Bank Of Canada reported 500 shares. Architects has 0% invested in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Jfs Wealth Advisors Limited Com holds 1,000 shares or 0% of its portfolio. Commercial Bank Of America Corporation De holds 0% or 1,117 shares. Morgan Stanley has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Pnc Group Inc reported 21,200 shares or 0% of all its holdings. 29,925 were accumulated by Barclays Public Ltd Company. Gp One Trading Lp holds 0% or 2,000 shares. Bancorp Of Montreal Can holds 0% or 1,600 shares. Glenmede Tru Company Na has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Wells Fargo Mn holds 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) or 14,725 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com